AI Stock Memo: KOD - Kodiak Sciences - RankAlpha

KOD

Rating buyTentativeAI Memo

Kodiak Sciences

As of 2026-03-27/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-03-27 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

high-coverage report lacks a dated company-specific catalyst beyond generic cadence

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Positive topline announced from GLOW2 Phase 3 (market-moving press release / 8-K) • 2026-03-26

Expected move: +14%

Biggest risk

Follow-up data or regulatory feedback raises additional evidence requirements, delaying submission and increasing cash-burn/funding risk; broader market re-rating back toward analyst median/low occurs if milestones slip.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

Positive GLOW2 topline leads to an expedited regulatory path and clear submission timeline; strong uptake expectations in the addressable diabetic retinopathy market and favorable pricing/coverage assumptions drive material upside to the anchor.

Research note

Recommendation

buy

Confidence

medium

As of

2026-03-27

Base target

$42

p=50%

Bull target

$70

p=20%

Bear target

$18

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Upcoming quarterly / investor update to quantify commercial readiness and cash runway
Regulatory pathway and potential filing (NDA/BLA) decision following GLOW2 topline
Positive GLOW2 topline leads to an expedited regulatory path and clear submission timeline; strong uptake expectations in the addressable diabetic retinopathy market and favorable pricing/coverage assumptions drive material upside to the anchor.

BearKey bullets

Commercial uptake and reimbursement uncertainty
Insufficient cash runway or dilutive financing
Post-topline safety/signaling or subgroup surprises

WatchKey bullets

Positive topline announced from GLOW2 Phase 3 (market-moving press release / 8-K)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $42 (p=50%)

Bull/Bear spread: +91% / -51%

Vs latest close: Bull +91% · Base +14% · Bear -51%

Scenario probabilities

Bull Target: $70 (p=20%)Base Target: $42 (p=50%)Bear Target: $18 (p=30%)

Commentary

Market sentiment turned strongly positive after the March 26-27 positive topline announcement; news flow and 8-K/IR updates are now the dominant drivers of price moves [#8-K-2026-03-27] [#IR-undated]. Analysts' consensus targets remain dispersed, leaving room for re-rating if management provides a clear submission timeline [#SERP-1].

As of 2026-03-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Upcoming quarterly / investor update to quantify commercial readiness and cash runway
Regulatory pathway and potential filing (NDA/BLA) decision following GLOW2 topline

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-03-27Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Below RA est

Provider

serper

Median (USD)

$26.15

Range (USD)

$14.00 - $52.50

Count

Query: Kodiak Sciences Inc Common (KOD) analyst consensus price target high low average

Kodiak Sciences (KOD) Stock Forecast & Price Target - Investing.com
Search result #1
According to projections from 6 analysts, the average 12-month price target for Kodiak Sciences is 35.500 USD, with a high estimate of 50 USD and a low ...
Extracted: $35.50, $50.00Open source
Kodiak Sciences Inc.: Target Price Consensus and Analysts ...
Search result #3
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 7 ; Last Close Price. 22.66USD ; Average target price. 35.50USD ; Spread / Average Target. +56.63%.
Extracted: $22.66, $35.50Open source
KOD / Kodiak Sciences Inc. (NasdaqGM) - Forecast, Price Target ...
Search result #5
The average one-year price target for Kodiak Sciences Inc. is $36.21. The forecasts range from a low of $14.14 to a high of $52.50. Read More.
Extracted: $36.21, $14.14, $52.50Open source
KOD | Kodiak Sciences Inc Common Analyst Forecasts
Search result #6
The median price target is $24.00 with a high estimate of $50.00 and a low estimate of $14.00. ... $14.00 Lowest Price Target. KOD Analyst Forecasts. Analyst.
Extracted: $24.00, $50.00, $14.00Open source
KOD Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
Search result #8
What is the analyst price target for KOD? Wall Street analysts have set a price target of $28.29, reflecting a 0.00% increase from the current stock price.
Extracted: $28.29Open source
Kodiak Sciences (KOD) Stock Forecast & Analyst Price Targets
Search result #9
The 7 analysts that cover Kodiak Sciences stock have a consensus rating of "Buy" and an average price target of $28.29, which forecasts a -26.65% decrease in ...
Extracted: $28.29Open source

Scenarios

Bull Target (Scenario probability)

$70 / p=20% prob

Base Target (Scenario probability)

$42 / p=50% prob

Bear Target (Scenario probability)

$18 / p=30% prob

Price $37 as of 2026-05-29

Nearest Scenario: Base (∆ 14%)

Targets vs latest close: Bull +91% · Base +14% · Bear -51%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-03-26
Positive topline announced from GLOW2 Phase 3 (market-moving press release / 8-K)
Kodiak announced positive topline results for the GLOW2 second Phase 3 study in diabetic retinopathy on March 26-27, 2026 (company press release / 8-K) — immediate commercial/regulatory implications to be disclosed in follow-up filings [#8-K-2026-03-27] [#IR-undated].
Prob 95.00% • Move 35.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Upcoming quarterly / investor update to quantify commercial readiness and cash runway
2026-06-25
Next quarterly results / investor update should disclose updated cash runway and commercial preparations tied to the GLOW program; use the company's 10-Q / IR schedule to monitor [#10-Q-2025-11-13] [#10-K-2025-03-27].
Prob 75% • Move 12% • Priced-in 30%

Long-term Catalysts

Months to a year

Regulatory pathway and potential filing (NDA/BLA) decision following GLOW2 topline
2027-03-27
Management is expected to outline next regulatory steps (e.g., planned submission timing or End-of-Phase-2/3 meeting) after the GLOW2 topline; monitoring planned 8-K/IR updates and upcoming investor communications for a formal submission timeline [#8-K-2026-03-27] [#IR-undated].
Prob 60% • Move 50% • Priced-in 20%

Risks

Commercial uptake and reimbursement uncertainty
Insufficient cash runway or dilutive financing
Post-topline safety/signaling or subgroup surprises
Regulatory requests for additional data or repeat studies

Peers

Symbol	Summary
DNTH	Small-cap ophthalmology/biotech peer with similar market cap and development-stage programs; useful comparator for regulatory/commercial pathway execution.
TRVI	Clinical-stage specialty biotech with comparable scale and single-program sensitivity; helps benchmark clinical-readout stock dynamics.
AGIO	Mid-size biotech with recent commercialization and regulatory experience; relevant for capital-allocation and launch-readiness comparisons.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Kodiak Sciences Inc Common (KOD) analyst consensus price target high low average
Analysis date: 2026-03-27